Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483974 | 1.00 | ADRB2 (0.52) | ADRB2ADRB1ADRB3CYP2D6ITGB3 | |
| SCHEMBL1483981 | 1.00 | ADRB2 (0.52) | ADRB2ADRB1ADRB3CYP2D6ITGB3 | |
| SCHEMBL14293136 | 0.97 | ADRB2 (0.49) | ADRB2ADRB1ADRB3CYP2D6ACHE | |
| SCHEMBL4407561 | 0.89 | CYP1A1 (0.48) | ADRB2ADRB1ADRB3CYP2D6ITGB3 | |
| SCHEMBL1483644 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL1483645 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL1484227 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL1484581 | 0.88 | ABCB1 (0.46) | ABCB1MAPT | |
| SCHEMBL4412877 | 0.87 | CYP3A4 (0.49) | CYP2D6MEN1KMT2AMAPTACHE | |
| SCHEMBL4399919 | 0.86 | MEN1 (0.47) | CYP2D6MEN1KMT2AMAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077294-A1 | R-(-) / S-(+)-7-[3-N SUBSTITUTED AMINO-2 HYDROXYPROPOXY] FLAVONES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-31 | — | — | US | claimed |
| EP-2057137-B1 | S-(+)-7-[3-N-SUBSTITUTED AMINO-2-HYDROXYPROPOXY]FLAVONES | COUNCIL SCIENT IND RES (IN) | 2013-10-23 | — | — | EP | disclosed |
| US-20110077294-A1 | R-(-) / S-(+)-7-[3-N SUBSTITUTED AMINO-2 HYDROXYPROPOXY] FLAVONES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-31 | — | — | US | disclosed |
| EP-2057137-A1 | R-(-) / S-(+)-7-[3-N-SUBSTITUTED AMINO-2-HYDROXYPROPOXY]FLAVONES | Council of Scientific and Industrial Research (IN) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008018089-A1 | R-(-) / S-(+)-7-[3-N-SUBSTITUTED AMINO-2-HYDROXYPROPOXY] FLAVONES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077294-A1 | R-(-) / S-(+)-7-[3-N SUBSTITUTED AMINO-2 HYDROXYPROPOXY] FLAVONES | HTR7, PNMT, PRMT7 | ADRB2 8/4885ADRB1 5/4885ADRB3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.